Prescient is a pharma services firm specializing in dynamic decision support and product and portfolio strategy. They partner with clients to turn science into value by helping them understand the potential of their molecules, shaping their strategic plans and allowing their decision making to be the biggest differentiating factor in the success of their products. When companies partner with Prescient, the molecules in their hands have a greater potential for success than the same science in the hands of their competitors.

Pharmaceutical

Prescient Healthcare Group

Ranjini is responsible for enabling organizational change and transformation at Prescient, working globally to help leaders and teams deliver on their growth strategies and transformational goals. She has spent over 20 years working for large multinational organizations, including PwC, Barclays, KPMG, Vodafone, EDF Energy and renewable energy company RES, and in that time she has led several large, complex projects through ambiguous and rapidly changing environments and helped clients realize value through their transformation agendas. She has worked in numerous countries across a variety of sectors, enabling transformations stemming from both organic and inorganic growth. She has a Bachelor of Engineering degree from Visvesvaraya National Institute of Technology, India, and a Master’s degree in human resources, accredited by the CIPD in the UK.

Ranjini Sachin

Erica Carlisle is the current Vice President at [Prescient Healthcare Group](/org/prescient-healthcare-group). Erica has also previously served as the Vice President of Strategy & Business Operations, Development at [Zymergen](/org/zymergen) from August 2018 to November 2021. Prior to that, they were a Principal at The Boston Consulting Group from July 2010 to July 2018. Erica has also worked as a Consultant at Clarion Healthcare, LLP from July 2007 to July 2008 where they were responsible for strategic analysis and implementation. In 2009, they worked as a Summer Consultant at BOSTON CONSULTING GROUP where they facilitated major organizational change for a senior client at a top 5 global pharmaceutical firm. Erica has a proven track record of being a strong leader and driver of change. Erica has demonstrated their ability to think strategically and implement solutions that create value for their clients.

Erica Carlisle began their educational career by earning a BA in Psychology from [Reed College](/org/reed-college). Erica then went on to earn an MBA in Management from the MIT Sloan School of Management. Finally, they earned a PhD in Psychology from [Princeton University](/org/princeton).

Erica Carlisle reports to Jamie Denison-Pender, CEO. Erica Carlisle works with Luke Solon - VP, Head of European Advisory, Gaurav Sharma - Therapeutic Area Group Director, and Michael White - Senior Vice President.

Erica Carlisle

Shweta Srivastava is the Therapeutic Area Group Director at [Prescient Healthcare Group](/org/prescient-healthcare-group). Shweta has over 12 years of experience in the pharmaceutical industry, with a focus on oncology and immuno-oncology.

Shweta started their career as a Senior Analyst at SmartAnalyst India Pvt, where they worked on projects for major pharmaceutical companies. Shweta then moved to IMS Health in October 2013, where they were a key member of the Oncology Centre of Excellence and led the Autoimmune Disorders syndicate reports.

In January 2017, they joined SmartAnalyst as Research Manager, working in Immuno-oncology. Shweta joined [Prescient Healthcare Group](/org/prescient-healthcare-group) in December 2016 as Therapeutic Area Group Director.

Shweta Srivastava works with Swati Kkatyal - President, India, Steve Padgett - President, and Ishaan Chaudhury - Senior Consultant. Their manager is Jamie Denison-Pender, CEO.

Shweta Srivastava

Gaurav Sharma is the current Therapeutic Area Group Director at [Prescient Healthcare Group](/org/prescient-healthcare-group). Prior to this, they worked as a Senior Global Feasibility Specialist, Site and Patient Access at [Syneos Health](/org/syneos-health) from September 2014 to May 2018. In this role, they were responsible for providing strategic recommendations for optimal patient recruitment, country recommendations for the launch of trial, site level feasibility and optimization, designing primary questionnaire and selecting key opinion leaders (KOLs) as principle investigators for the trials. Gaurav also worked as a Clinical Informatics Specialist - Enrolment Rate Benchmarking, Country Selection and Competition Scenario in response to request for proposal (RFP) and request for information (RFI) for clinical trials.

Before joining [Syneos Health](/org/syneos-health), Gaurav Sharma worked as a Manager - Clinical and Scientific Analytics at [BioXcel Corporation](/org/bioxcel-corporation) from March 2013 to September 2014. In this role, they were responsible for managing clinical and scientific analytics for PharmGPSTM (analytical platform) for preclinicals. Gaurav was also the solution architect and team leader for pivotal key opinion leaders (KOLs) management. Gaurav designed key robust strategies involving performance benchmarking & clinical development and developed key recommendations for clients on various bio-technologies built around Orphan indications. Gaurav also developed new models of portfolio augmentation (target selection, indication prioritization) to help clients in taking key research and development decisions.

Gaurav Sharma has a Doctor of Philosophy (PhD) in Nanotechnology, Formulation Development and Pharmacology from the [University of Strathclyde](/org/university-of-strathclyde). Gaurav also has a M.S. (Pharmaceutics) in Formulation and Pharmacology from the National Institute of Pharmaceutical Education and Research. Gaurav completed their B. Pharma (Hons.) in Pharmacy from the Indian Institute of Technology (Banaras Hindu University), Varanasi.

Some of their coworkers include Rakesh Verma - President, Intelligence & Insight, Tanya Casimiro - Director, and Michael White - Senior Vice President. Gaurav Sharma reports to Jamie Denison-Pender, CEO.

Gaurav Sharma

Jyotsana Chaudhary is currently the Therapeutic Area Group Director at [Prescient Healthcare Group](/org/prescient-healthcare-group). Prior to that, they were with IMS Health as the Associate Manager of Oncology from July 2012 to June 2016. From July 2016 to July 2019, they worked at SmartAnalyst as a Senior Research Manager of Oncology. Before that, they were a Senior Analyst of Pharmaceuticals and Healthcare at SmartAnalyst from June 2007 to July 2012.

[

Jyotsana Chaudhary has a Master of Science (M.Sc.) in Clinical Research from Cranfield University/ICRI and a Bachelor of Science (B.Sc.) in Zoology from Delhi University.

Jyotsana Chaudhary reports to Jamie Denison-Pender, CEO. They work with Michael White - Senior Vice President, Rakesh Verma - President, Intelligence & Insight, and Debbie Allman - Senior Vice President.

Jyotsana Chaudhary

Andrew Mcmeeking is the current Global Finance Director at [Prescient Healthcare Group](/org/prescient-healthcare-group). Andrew has over fifteen years of experience in finance and has held various positions in companies such as gyro and [Prescient Healthcare Group](/org/prescient-healthcare-group). In their previous position as UK Finance Director at gyro, they were responsible for overall commercial functions, finance functions of all UK offices, internal control environment, and financial reporting. Andrew has also been responsible for budgeting, forecasting, and negotiating contracts with clients, suppliers, and third parties. Under their leadership, Gyro underwent the acquisition of agencies in Manchester, London, Stockholm, Paris, and Munich. Andrew has also performed full financial reviews of the Paris, Hamburg, and San Francisco operations for the group CFO and recommended a number of changes to improve these underperforming finance functions. Andrew Mcmeeking is a highly skilled finance professional with a proven track record in improving efficiency and profitability in organizations.

Andrew Mcmeeking has a BAcc (Hons) from the University of Dundee in Accountancy. Andrew also attended Grove Academy, Craigiebarns, and Breadalbane Academy.

Their manager is Jamie Denison-Pender, CEO. Some of their coworkers include Swati Kkatyal - President, India, Gerald Dunstan - Chief Strategy Officer, and Ishaan Chaudhury - Senior Consultant.

Andrew Mcmeeking

Tanya Casimiro is the Director at [Prescient Healthcare Group](/org/prescient-healthcare-group). Tanya has over fifteen years of experience in the healthcare industry, including research, teaching, and administration. 

Casimiro began their career as an intern at [Dana-Farber Cancer Institute](/org/dana-farber-cancer-institute-inc) in 1997. Tanya later became a Research Technician at The Neurosciences Institute and then a Culture Technician at [Brandeis University](/org/brandeis-university). In 2005, they started working as a Postdoctoral Researcher at Albert Einstein College of Medicine, where they stayed for nine years. In 2014, they left to join Russo Partners, LLC as an Assistant Account Executive. Tanya held this position for two years before joining [Prescient Healthcare Group](/org/prescient-healthcare-group) in 2016. 

Casimiro has a passion for healthcare and improving the lives of others. Tanya is dedicated to their work and takes great pride in their accomplishments.

Tanya Casimiro's educational career began with a Bachelor of Science in Biology & Psychology from [Boston College](/org/boston-college). Tanya then went on to earn their Doctor of Philosophy in Molecular and Cellular Neuroscience from Albert Einstein College of Medicine.

Their manager is Jamie Denison-Pender, CEO. They work with Swati Kkatyal - President, India, Rakesh Verma - President, Intelligence & Insight, and Shweta Srivastava - Therapeutic Area Group Director.

Tanya Casimiro

Nishika Bhan is a healthcare professional who has been working in the industry for over 7 years. Nishika started their career as a research analyst and has since held positions of increasing responsibility, culminating in their current role as director at [Prescient Healthcare Group](/org/prescient-healthcare-group). Nishika has a proven track record of success in leading and managing teams of healthcare professionals and is passionate about improving patient outcomes.

Nishika Bhan has a masters from the Amity Education Group and a bachelors from Delhi University.

Nishika Bhan

Claudio Jouanneau is currently the Director of Advisory at [Prescient Healthcare Group](/org/prescient-healthcare-group). Prior to this, they worked as a Senior Consultant at [IQVIA](/org/iqvia) from September 2017 to September 2020. Claudio's responsibilities there included leading client presentations, managing relationships with clients, preparing business proposals, and managing teams of consultants. Claudio has worked with clients in the pharmaceutical sector, medtech, and consumer health. Claudio has also participated in recruiting tasks, built relationships with universities and business schools for recruiting purposes, performed internal trainings for junior team members, and led the development of a Welcome Pack to help new joiners adapt to the firm.

Claudio Jouanneau has a background in engineering, having studied industrial and chemical engineering at the IQS School of Engineering - Universitat Ramon Llull. Claudio also holds an Executive Master in Business Administration (MBA) from [IESE Business School](/org/iese-business-school) - University of Navarra. Prior to their engineering studies, they completed a Baccalauréat scientifique with mention "Bien" from Lycée Français de Barcelone.

Claudio Jouanneau reports to Debasish Talukdar, President, Advisory. Some of their coworkers include Olga Fidalgo Gonzalez - AVP, Advisory, Emma Leung - Senior Director, and Kevin Baruzzi - VP, Advisory.

Claudio Jouanneau

Finance and Business Operations function. She has strong skills in financial planning and reporting along with good business acumen, supporting both the executive board and management team in decision making.

Prior to joining Strategic North, Anna trained and qualified for her CIMA accountancy qualification at N Brown Group PLC. Over the last 20+ years, she has held various roles in finance, including roles at Marks & Spencer, TDG and a number of SMEs.

Anna Rockall

Jeanne is an Vice President at Prescient. Prior to joining Prescient, she spent more than 25 years providing strategic insight and planning support to the biopharmaceutical industry. Jeanne has held leadership roles at various companies including [EMD Serono](/org/emd-serono-inc) and Genzyme. She brings a depth of biopharma experience in brand and strategic planning, indication prioritization, competitive intelligence, workshop design and facilitation, and integration of multiple external perspectives to inform decision-making. At Prescient, Jeanne will leverage her expertise in rare diseases, multiple sclerosis, immunology, inflammatory diseases and fertility to grow and develop client relationships and lead client engagements.

Jeanne Penn

Jatin is a Senior Director and has been with Prescient since 2014. He holds a master’s degree in biotechnology from the University of Manchester and he has worked within the pharmaceutical analysis divisions of major organizations such as Bloomberg. At Prescient, Jatin has directed several global projects while working across domains including immunology, oncology, hematology, neurology, nephrology, endocrinology, respiratory disease and biosimilars. He applies his broad experience and strategic mindset to a variety of engagement types ranging from intelligence-driven consultative projects to strategy development support.

Jatin Gupta

Katy is a Associate Vice President in the Advisory business. Since earning her master’s degree in bioscience from [Keck Graduate Institute](/org/keck-graduate-institute), she has acquired several years of experience in life science management consulting, advising clients on brand, commercialization and corporate portfolio strategy engagements. She has focused on late-stage, pre-launch assets across various disease areas, including oncology, hematology, dermatology and rare diseases. At Prescient, Katy’s focus is on driving the growth of the Advisory team by ensuring engagements are of high quality, expanding Prescient Advisory’s presence and supporting team professional development.

Katy Chun

Harminder is an Vice President and has been delivering high-impact projects to our clients since 2010. He has an MS degree in chemistry from [Virginia Commonwealth University](/org/virginia-commonwealth-university) and a BPharm degree from Panjab University. He is also a registered pharmacist. Before joining Prescient, he worked in pharmaceutical product manufacturing, regulatory and corporate departments. At Prescient, Harminder has focused on analyzing competitors and market scenarios for biosimilar, generic and novel products. He has also worked at building client relationships and motivating teams to better serve client needs.

Harminder Bhatia

Mladen is one of our Senior Directors and is responsible for leading engagements across different therapeutic areas. He received his PhD in microbiology from the [University of Minnesota](/org/university-of-minnesota) and completed his postdoctoral research at [Columbia University](/org/columbia-university). Before joining Prescient, Mladen oversaw analyst teams and market research portfolios at [Decision Resources Group](/org/context-matters) across various therapeutic areas, including rare and infectious diseases. Previously, he worked at Merck & Co. and MedImmune/AstraZeneca, where he led projects focused on the discovery of novel anti-infectives for the treatment and prevention of serious bacterial infections.

Mladen Tomich

Christina joined Prescient as the Director of Global Marketing and heads up all marketing and communications functions. After earning a master’s degree in pharmaceutical business, she pursued careers in both non-profit and commercial sectors. Her experience includes leading marketing strategy for global oncology teams, as well as regionally for the Americas and in emerging markets with [Kantar](/org/kantar)’s Health Division. Christina is responsible for elevating the positioning and messaging of the Prescient brand through the development of strategic marketing programs and thought leadership initiatives.

Christina Maffei

Mark is the Senior Vice President of our North American business. After completing a PhD in biochemistry at [The Ohio State University](/org/the-ohio-state-university), he spent more than 10 years running GSK’s competitive strategy function and 10 years as a key member of [Covance](/org/covance)’s executive strategy team. Mark engaged with Prescient throughout his tenure with GSK and [Covance](/org/covance) before joining us in 2013. He is responsible for establishing, solidifying and expanding client relationships by engaging with industry executives and bringing clarity to our solutions.

Mark Little

Tarun is spearheading the development of InflexionRx. He obtained his Master’s degree in computer applications from M.B.M Engineering College, and has more than 18 years of experience in product management, enterprise application design and development and entrepreneurship. He has worked with small- to medium-sized technology start-ups and is an expert in product ideation, conceptualization, development from proof of concept to final product, and market releases. At Prescient, Tarun’s role involves leading and delivering a software platform that creates value for our clients and drives efficiencies within our project teams.

Tarun Ojha

Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgery before joining Andersen Consulting (now known as [Accenture](/org/accenture)), eventually becoming the global leader of [Accenture](/org/accenture)’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.

Nick Edwards

Swati is President of our sizable India-based business operations. She has an MSc in biotechnology and pharmacology, and an MBA from the University of Sheffield. After joining us in London in 2008, she moved to India in 2010 to set up the New Delhi office, which she has built into a critical part of our business. She has also been responsible for setting up the software development team and the analytics center for Prescient in India. Swati has extensive experience in consulting biopharma companies on new and mature brand planning strategies. She has directed engagements across multiple therapeutic areas and geographies, with a focus on the APAC region.

Swati Kkatyal

Luke is a Vice President and Head of our European Advisory business based out of our London office. After studying medicine and working as a doctor in the UK for several years, Luke spent the rest of this career in consulting roles at various firms including [McKinsey & Company](/org/mckinsey-company) and Strategy&. He has led and delivered projects across most of the pharmaceutical value chain, as well as multiple therapy areas and geographies. Luke brings deep experience in value and access strategy, portfolio strategy, clinical development strategy, medical affairs strategy, commercial due diligence and life cycle management. Luke prides himself on his collaborative working style, both with clients and colleagues. At Prescient, Luke is responsible for growing our European advisory business and helping our clients address their biggest market access hurdles to maximize their brand’s value.



Luke Solon

RUHI SAXENA

Sanya Behl

Deepak Prajapati

Amol Padgaonkar is a Director in our Intelligence & Insight business with over seven years of experience strategically supporting clients across the life sciences industry. In particular, Amol is deeply familiar with the oncology, hematology and inflammatory disease therapeutic areas; with expertise across various forms of engagements, Amol’s primary strategic focus includes early asset, asset life cycle and portfolio/therapeutic area planning. He enjoys serving as a critical thought partner for clients, leveraging his disease area content expertise and strategic insights to drive actionable and innovative solutions. Prior to joining Prescient, Amol received his PhD in molecular biology and cancer genetics from the Temple University School of Medicine in Philadelphia and completed his postdoctoral research at Mount Sinai School of Medicine in New York, where his thesis focused on the discovery and development of novel oncogenic kinase targets and inhibitors in triple-negative breast cancer.

Amol Padgaonkar

Peter is one of our Directors and works across our Advisory and Intelligence & Insight business units. After earning a degree in life sciences, he gained a first-class master’s degree in business at [Edinburgh Napier University](/org/edinburgh-napier-university) and a postgraduate qualification in health economics at Aberdeen University. Peter has held scientific, development and commercial leadership roles within the CRO, pharmaceutical and biopharmaceutical industries with [Charles River Laboratories](/org/charles-river-laboratories-international-inc), [Kyowa Kirin](/org/kyowa-kirin) and Ablynx NV, respectively. He has been the Global Launch Director for two orphan drug monoclonal antibody launches, both for the treatment of rare diseases. At Prescient, Peter is responsible for leading successful Intelligence & Insight engagements, growing revenue within existing accounts and providing an expert understanding of the evolving EU biopharmaceutical market. In addition, Peter provides advisory expertise in commercial launch strategy, R&D portfolio and project management, pricing and market access, competitive strategy and opportunity assessment across various therapeutic areas including metabolic bone disease, oncology, hematology, pain management and men’s health.



Peter Donachie

Emmanuel is a Director for the Prescient Intelligence & Insight business. He holds an MD from the University of Cincinnati College of Medicine and an MSc in immunology from the [Medical University of South Carolina](/org/medical-university-of-south-carolina). He worked at University of Cincinnati Health for a year while conducting clinical and preclinical research focused on liquid tumors and molecular biology. He then co-founded a consulting firm to help integrate the use of technology into the practice of medicine, originally centered on the implementation and optimization of electronic health record systems. After several years growing the business, Emmanuel entered the pharmaceutical sector as a clinical trial manager in hematology/oncology. At Prescient, Emmanuel leverages his clinical and research experience to support clients as they navigate the complexities of bringing new therapies to patients in need.



Emmanuel Reyes-Cortes

Ishaan joined the team in January 2021 as a Consultant. After receiving his undergraduate and master’s degrees from UCL in biology and molecular medicine, respectively, he started his career in the NHS in a variety of administrative and research positions at University College Hospital, London. He then transitioned to healthcare market research spending several years at Hall & Partners where he worked across different therapy areas. At Prescient, Ishaan actively seeks opportunities to use his research and storytelling capabilities to deliver valuable insights to clients.

Ishaan Chaudhury

Jessica Gill

Olga Fidalgo Gonzalez is the AVP, Advisory at [Prescient Healthcare Group](/org/prescient-healthcare-group). Olga has over 20 years of experience in the healthcare industry, including working as the Corporate Director Business Development & Innovation at Ferrer from January 1999 to September 2020. In their current role, they are responsible for providing strategic and operational advisory services to clients in the life sciences industry.

They are on a team with Claudio Jouanneau - Director, Advisory, Emma Leung - Senior Director, and Katy Chun - Associate Vice President. Olga Fidalgo Gonzalez reports to Debasish Talukdar, President, Advisory.

Olga Fidalgo Gonzalez

Amit kumar

Cameron is a Senior Director in our Intelligence & Insight business. He earned his PhD in biophysical chemistry from the University of Glasgow, MSc in chemistry from the University of Strathclyde and MBA from Strathclyde Business School. He has over 15 years of experience in the pharma and biotech industries. He spent his early career working in R&D and manufacturing in established companies, before joining a start-up to lead the development, launch and global sales of a novel product. He then moved to the consulting sector where he worked with established brands and seed-stage companies. Most recently, he led the BD, licensing and IP management functions at a company developing allogeneic CAR-T assets. At Prescient, Cameron is responsible for leading high-quality engagements with new and existing clients and applying his knowledge and experience to answer their strategic business questions.



Cameron Mackenzie

Easha is a Senior Director in our Intelligence & Insight business. She has a degree in life sciences and an MBA in marketing and strategy from the Indian School of Business. She has more than 12 years of industry experience and a proven track record of turning compelling market insights into differentiated strategies and solutions. She has worked across the business value chain from R&D, new product launch and commercialization to life cycle management of brands in various therapy areas. She has held strategic and marketing roles in various biopharma companies and led the launch of two blockbuster products in oncology. At Prescient, Easha leads global competitive intelligence programs for leading biopharma companies.



Easha Ghildyal

Emma is a Senior Director within the IRx team. She has over 10 years of experience delivering technology and organisational transformation, including: process design, setting up centres of excellence, management reporting and analytics across a range of companies, countries, and industries. She has worked in the UK National Health Service and private pharmaceutical companies. Her role drives our IRx strategy, developing frameworks and ways of working to ensure a consistent, quality structure for our clients; working with both client and internal teams to rollout the platform and embed this within our business and our client interactions.



Emma Leung

Victoria is a Vice President and the Chief Talent Officer. She has a Bachelor’s degree (Hons) in economics from [Nottingham Trent University](/org/nottingham-trent-university), as well as several accounting and human resources certifications. Victoria spent more than 20 years in senior leadership positions at [KPMG](/org/kpmg) across Europe and Asia, where she developed extensive experience and a proven ability to implement change in complex and cross-cultural environments. At Prescient, her role involves working with senior stakeholders to effectively prioritize and execute the people activities needed to achieve defined strategic objectives.

Victoria Muir

David is a Senior Vice President at Prescient and prior to that was a founding partner and Client Relationship Director at Strategic North. He has over 25 years’ experience in the pharma industry across market research and strategic brand building. He has been part of a leadership team that has built three successful pharma consultancy practices. He brings deep expertise in understanding customer beliefs and behaviors and translating these insights into brand strategy. He combines this with great people skills to ensure clients are inspired about the future possibilities for their brand. He is passionate about engaging with a diverse range of stakeholders in healthcare and positively impacting patients’ lives.

David Coleiro

Debbie is a Senior Vice President in our Commercial Advisory business. She has a track record of more than 25 years working in a variety of global and national marketing roles for AstraZeneca followed by the leap to the consultancy world, where she built a successful brand building and insights consultancy called Strategic North with fellow co-founders David, Steve and Michael. Debbie is passionate about working collaboratively with clients to build successful brands starting from early in the life cycle through to launch and beyond, bringing substantial knowledge and experience in creating actionable strategies that achieve tangible results.

Debbie Allman

Michael, a Senior Vice President at Prescient, was founder and Business Unit Director of Strategic North. Michael draws on a wealth of knowledge and experience from building a successful global consultancy, as the Head of Client Services for a healthcare communications agency and being a Global Commercial Lead in corporate, all underpinned by his MBA and degree in biochemistry. He embodies the intellect and creative energy that shapes great brand strategy combined with the commercial astuteness to realize the full value of a brand, portfolio or franchise.

Michael White

Steve is President of our Commercial business. Prior to this, he was Managing Director and one of the founding partners of Strategic North. He spent the first part of his career in brand and innovation consultancy, working with a wide range of international brand-led businesses. He brings a forward-looking and customer-centric brand mindset to everything we do.

With over 30 years’ experience, Steve is quick to see the big picture, never one to accept the status quo and a passionate believer in the power of the team – all qualities he brings to bear on everything he does, whether it’s your brand or ours.

Steve Padgett

Sarah is our Head of People and Culture and joined Strategic North when it was founded in 2010. She has over 25 years’ experience in HR, operations and finance, working with some of the biggest PR and marketing agencies in the UK and Australia. Sarah’s energy, passion and enthusiasm put her at the heart of the Strategic North culture. She is a highly skilled people person, responsible for all elements of our People & Culture strategy, ensuring we recruit, develop and retain the right people to deliver against our overall business strategy. She makes sure that the unique culture we have created is protected and sustained through living our values.

Sarah Dangerfield

Alex Panayi serves as Prescient’s CFO. After studying at the London School of Economics and qualifying as a chartered accountant at KPMG, Alex spent over 20 years working for large multinational organizations, including Thorn EMI, BAA and Lend Lease. He most recently spent 14 years at global sustainability consultancy ERM, where he successfully supported the business through three private equity transactions. At Prescient, Alex will oversee the company’s finance functions.

Alex Panayi


Diane Whelan has been recently appointed as our first Head of Learning, based out of the London office. She will work closely with Gerald Dunstan, Chief Strategy Officer, helping to shape the future of Prescient. Her remit is to build a Prescient Academy, focussed on developing those critical skills and experience that enables us to offer a world class service to our clients, as well as providing development pathways for our talented team. Diane brings a wealth of global learning experience, across many sectors, gained in both corporate roles, and working as a consultant in leadership and management development. She has worked within Professional Services for the last ten years, building consulting, leadership, professional and business development capability. Diane holds a Masters Degree in Management Learning from Lancaster University, is a Fellow of the Learning Performance Institute and a Chartered Member of the CIPD.

Diane Whelan

Gerald is the Chief Strategy Officer, based out of the London office. He is a molecular biologist by training and completed his PhD in anti-microbial drug discovery under the highly regarded Glaxo Scholarship program. After several years of working across drug discovery and development, both in Europe and in North America, Gerald made the transition to the world of management consulting. Since then, he has spent the last 20 years working exclusively with the healthcare and life sciences sectors globally with payers, providers and life science companies ranging from start-up biotechs to top-five pharmaceutical companies. He has worked across the value chain encompassing R&D strategy, clinical development strategy, portfolio strategy, medical affairs strategy and value and access strategy. At Prescient, Gerald leads in shaping and executing the ambitious growth strategy to deliver on the company's vision and mission.

Gerald Dunstan

Paula joined our team in 2015 and is a now a Director in our Intelligence & Insight business. She holds an MSc in medical biology from the University of Oviedo, Spain. She began her academic research career at the University of Roehampton London, investigating the mechanism of metastasis in multiple tumors. At Prescient, Paula coordinates a wide range of engagements with our clients within the oncology space, with a particular focus on drug development strategy and competitive pipeline analysis. She uses her deep knowledge and expertise across treatment paradigms and market dynamics in oncology to advise our clients’ strategies in this area.



Paula Palacios Fernández

Priya is a Director in our Intelligence & Insight business. She earned her PhD in molecular biology from the New Jersey Medical School and MBA in pharmaceutical management and marketing from Rutgers Business School. She has over 15 years of healthcare experience, particularly in the realm of commercial and clinical insights and strategy development. Within her previous roles, she has served as a subject matter expert and was a trusted advisor for her clients. Priya has co-authored several peer-reviewed scientific articles and industry-relevant white papers. At Prescient, Priya is responsible for driving growth within our Intelligence & Insight business, managing key business accounts and providing strategic leadership in coaching teams to deliver successful engagements.



Priya Kar

Sugandh is a Senior Director in the Intelligence & Insight business. She holds an MS in biotechnology and has over 14 years of experience in setting up new businesses and delivering strong commercial performance and growth in the healthcare consulting, research and intelligence sectors. In her previous roles, Sugandh has led multiple engagements with biopharmaceutical and healthcare companies in the domains of commercial strategy, market access, research, and intelligence across various disease segments. At Prescient, Sugandh is responsible for driving growth within our Intelligence & Insight business by developing successful engagements with clients and coaching teams to deliver high-quality insights and impact.

Sugandh Sharna

Reena is a Director in the Intelligence & Insight business. With more than a decade of clinical and pharmaceutical industry experience, Reena’s expertise spans consulting, medical affairs, clinical development and medical writing across the immunology, oncology, rheumatology and cardiology areas. She practiced as a physician before transitioning to work with various pharmaceutical companies. In addition to her medical degree, she holds a post-graduate certifiate in Quality and Accreditation of Health Care Organizations. At Prescient, Reena leads multi-dimensional engagements for global pharmaceutical organizations to support their business intelligence strategies across various stages of the product life cycle.

Reena Telang

Anamika heads the Talent and Performance Management Function of the India operation. She is an alumna of IIM Raipur and has an MBA in human resource management. She has more than 10 years of experience in the field of human resources and has worked in diverse industries. At Prescient, Anamika is responsible for talent acquisition and talent development, and she continues to play a pivotal role in the growth and development of our India team.

Anamika Gera

Kevin is a Vice President in the Advisory business and leads the Boston office. He earned his BSc in neuroscience and economics from [Brown University](/org/brown-university) and has since worked in life sciences and biopharma strategy consulting, spending the better part of a decade at [ClearView Healthcare Partners](/org/clearview-healthcare-partners) prior to joining Prescient. Kevin has led multiple engagements across a range of therapeutic areas and geographies. He is experienced in target product profile development and evaluation, therapeutic area and indication prioritization, competitive strategy, opportunity assessment, due diligence, life cycle management and clinical development strategy. At Prescient, Kevin ensures client satisfaction through high-quality, tailored and targeted recommendations.

Kevin Baruzzi

Ashima, a physician by training, is a Senior Director at Prescient. Ashima’s career has included positions with medical institutions, insurance companies and consulting firms. At Prescient, which she joined in 2014, she has worked extensively in biosimilars, hematology and rare disease. She leads client engagements related to strategic BD&L decisions, CI, product label design, commercialization planning, life cycle management and financial modeling.

Ashima Sharma

Kallal is one of the longest-serving members of our India-based team. He has master’s and doctoral degrees in biotechnology, as well as a master’s degree in business administration. After holding various academic research posts in oncology, Kallal became a Lead Scientist at Connexios Life Sciences, where the focus of his group was to design in vitro and ex vivo assays reflecting human pathologies in type 2 diabetes mellitus and to test the efficacy of in-house drugs. Since joining Prescient in 2010, Kallal has managed new product and mature product brand planning projects in the areas of neurology, oncology, immunology and diabetes in both regulated and semi-regulated markets.

Kallal Pramanik

Nick, a Senior Director, has a PhD in pharmacology from the [University of London](/org/university-of-london) and conducted postdoctoral research at London’s Royal Postgraduate Medical School. He began his career in the pharmaceutical industry as a senior scientist to lead the pharmacology effort on discovery research projects in airway diseases at Rhône-Poulenc (now [Sanofi](/org/sanofi)) and in asthma and type 2 diabetes at SmithKline Beecham (now GSK). He then spent nearly 19 years as a senior equity analyst at Mirabaud Securities and Jefferies, with responsibility for the pharmaceutical and biotechnology industries. At Prescient, Nick supports clients as a subject matter expert in oncology and haematology.

Nick Turner

Rakesh is the President of our Intelligence & Insight business. After earning a degree in Veterinary Medicine, he completed his Master’s in immunology and PhD in immunology/oncology at Imperial College, School of Medicine, London. He was then recruited by oncology biotech firm Antisoma, which specialized in the development of antibodies based therapeutics for oncology. After working for more than a decade in oncology drug development, he joined Prescient in 2007. His renowned expertise in the development and commercialization of biologics makes him an extremely valuable asset to our oncology, immunology and biosimilar clients.

Rakesh Verma

Paul oversees our business activities in North America. Since completing his PhD in chemistry at [Stony Brook University](/org/stony-brook-university), he has spent more than 20 years providing guidance and support to the healthcare industry. He has held leadership roles at various consulting firms, including [Deloitte](/org/deloitte) and Quintiles, that engage with biopharmaceutical and medical technology companies in nearly all functional areas, including sales, marketing, medical affairs, business development and supply chain. Paul’s focus at Prescient is helping our clients achieve and sustain peak commercialization targets across a wide range of therapy areas.

Paul Harney

Aviral is an Vice President at Prescient. He completed his MBBS and MS degrees at Jawaharlal Nehru Medical College, India, and his MBA at [IESE Business School](/org/iese-business-school), Spain. Aviral has developed a strategic understanding of both the clinical and commercial sides of the life sciences industry from working as a physician for eight years and holding strategic consultancy roles at GlaxoSmithKline Biologicals and Grail Research. Since joining Prescient in 2010, Aviral has examined all aspects of the product life cycle for companies developing biologics, biosimilars and generics, OTC medicines, vaccines and medical devices within CVMD, respiratory disease, gastroenterology, immunology, dermatology, neurology and ophthalmology.

Aviral Maheshwari

Ben is an Vice President and supports both our East and West Coast clients in the US. He holds a BSc in biomedical sciences and an MSc in biomedical engineering, and gained eight years’ experience in biotech prior to joining Prescient in 2010. Ben has held progressively more senior roles at Prescient, which has given him a deep understanding of what is needed to build and motivate teams that deliver results with a high degree of client satisfaction. Ben has also been closely involved in managing projects across multiple therapeutic areas, including oncology, immunology and biosimilars.

Ben Doran

Courtney, our Associate Vice President of Operations, joined Prescient in 2012. After earning a master’s degree in Spanish translation, she pursued a job opportunity in Bogotá, Colombia, where she translated medical, legal and technical texts and designed an assessment program to monitor the quality of her fellow translators’ work. Courtney is responsible for various operational aspects of our business, including quality control, compliance and US resourcing.

Courtney Carlson

Nadia joined the Prescient team as the US Financial Controller and HR Director. After earning her accounting degree, she developed financial expertise through working with high-end retail and luxury brands headquartered in New York City. While working in retail, Nadia was responsible for the financial reporting and oversight of nationally recognized brands with a presence across the country. The technical expertise and business acumen that she has acquired over the past 15 years have proven to be an invaluable asset to our organization.

Nadia Gonzalez

Anthony is one of the longest-serving members of our team. He earned his PhD in pharmacology before becoming a postdoctoral researcher at the [University of Southampton](/org/university-of-southampton). From there, he joined the world of healthcare market research, working for the likes of MMR International, IMS Health and NOP World (now GfK). He has consulted across the therapeutic spectrum and throughout the product life cycle but particularly enjoys developing clinical strategies within oncology, infectious disease and cardio-metabolic diseases.

Anthony Starling

Jamie is our CEO and a career consultant, having spent more than 20 years growing and managing pharmaceutical-focused insight and advisory firms. In 2007, he became managing director of a global competitive strategy firm and led the company’s transition from an industry generalist to a biopharmaceutical specialist. He rebranded the company to Prescient in 2010, led a management buyout in 2014 and the investment by Baird Capital in 2017. Jamie remains actively involved with our clients, mainly focusing on brand planning, mature brand strategies and strategy workshops.

Jamie Denison-Pender

Robert is a Director for the Prescient Intelligence & Insight business. He earned his MSc in biomedical engineering from [Columbia University](/org/columbia-university) and his BASc in biomedical engineering from [Bucknell University](/org/lombahdo). He has over 10 years of experience in biopharmaceutical commercial strategy, market insights, data and analytics, business reporting and competitive intelligence. His market analysis has been featured in [The New York Times](/org/new-york-times), [The Wall Street Journal](/org/the-wall-street-journal), Forbes and [Thomson Reuters](/org/thomson-reuters). Before joining Prescient, Robert led diverse projects in strategy and intelligence for several biopharmaceutical companies including Juniper Pharma and [Intarcia Therapeutics](/org/intarcia-therapeutics) in various therapeutic areas, including oncology, women’s health, rare diseases and diabetes. At Prescient, Rob is responsible for driving the Intelligence & Insight team’s growth by ensuring engagements are of high quality, expanding Prescient’s presence in the greater Boston area and supporting team professional development.



Robert Littlefield

Debasish is the President of our Advisory business. He started his career as a physician and holds an MBA from the [IIM Calcutta](/org/iim-calcutta). After a brief stint at P&G, he made the move to strategy consulting, and spent ten years at [Bain & Company](/org/bain), where he was a leader in the healthcare practice. Debasish has extensive international experience across US, EU and APAC markets advising biopharma leaders on value creation through corporate, business unit, disease area and product-focused strategies.

Debasish Talukdar

Gordon is a Senior Director in our Intelligence & Insight business. He earned his MBA in market and strategy from Carnegie Mellon University and his BA in biochemistry from the University of Pennsylvania. He has over 15 years of dedicated oncology experience in market research and competitive intelligence. Before joining Prescient, Gordon led teams working on projects across the development timeline at Kantar Health, AlphaImpactRx (now part of IQVIA) and Psyma . At Prescient, Gordon is responsible for driving our business growth by expanding our presence, ensuring high-quality engagements and supporting team development.

Gordon Gochenauer

Elisavet is a Vice Prescient and joined Prescient in 2008. She holds a PhD in molecular immunology and an MSc in medical genetics from [Brunel University London](/org/brunel-university-london), as well as a BSc in biology from the Royal Holloway University of London. As a consultant to the pharmaceutical industry, Elisavet has gained extensive experience in various aspects of drug development and commercialization, strategic marketing and life cycle management, providing critical analysis and recommendations to brand teams supporting new and existing products in oncology, malignant and non-malignant hematology, vaccines, rare diseases and other areas. Elisavet uses her expertise in evidence gathering to identify key unmet needs, gaps in strategy, opportunities for differentiation and potential threats.

Prescient Healthcare Group

Org chart

Teams

Leadership Team

CEO and Executive Team

Board of Directors

Discover similar companies